Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879832 | 0.78 | HSD17B10 (0.40) | ELANENPSR1HSD17B10ALDH1A1MAPT | |
| SCHEMBL28171008 | 0.76 | HSD17B10 (0.39) | ELANENPSR1HSD17B10ALDH1A1MAPT | |
| SCHEMBL29642546 | 0.76 | HSD17B10 (0.39) | ELANENPSR1HSD17B10ALDH1A1MAPT | |
| SCHEMBL26614158 | 0.76 | HSD17B10 (0.39) | ELANENPSR1HSD17B10ALDH1A1MAPT | |
| SCHEMBL159458 | 0.76 | GPR3 (0.52) | HSD17B10ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL18475321 | 0.76 | HSD17B10 (0.39) | ELANENPSR1HSD17B10ALDH1A1MAPT | |
| SCHEMBL29057018 | 0.76 | KDM4E (0.43) | ELANENPSR1HSD17B10ALDH1A1MAPT | |
| SCHEMBL29511366 | 0.76 | GPR3 (0.52) | HSD17B10ALDH1A1MAPTSMN1; SMN2LMNA | |
| SCHEMBL29697555 | 0.76 | ELANE (0.39) | ELANENPSR1HSD17B10ALDH1A1MAPT | |
| SCHEMBL27469683 | 0.76 | ELANE (0.39) | ELANENPSR1HSD17B10ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863185-A | novel monomers and polymers | 巴斯夫欧洲公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-107207715-A | Novel polymer compositions and use of these polymer compositions as viscosity modifiers | 巴斯夫欧洲公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-107075243-A | Novel polymer compositions and use of these polymer compositions as dispersants | 巴斯夫欧洲公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-2137141-B1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | UNIV ABERDEEN (GB) | 2015-12-02 | — | — | EP | disclosed |
| US-8524778-B2 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | PIMCO 2664 LIMITED (GB) | 2013-09-03 | — | — | US | disclosed |
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2010-11-11 | — | — | US | disclosed |
| EP-2137141-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | The University Court of The University of Aberdeen (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008114022-A1 | BIPHENYL-4-YL-SULFONIC ACID ARYLAMIDES AND THEIR USE AS THERAPEUTIC AGENTS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-09-25 | — | — | WO | disclosed |
| EP-1458691-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051274-A2 | BENZODIAZEPINE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286266-A1 | Biphenyl-4-yl-sulfonic acid arylamides and their use as therapeutic agents | ARSA, SOST, AHR | ELANE 1571/4885NPSR1 439/4885HSD17B10 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.